{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:57:24Z","timestamp":1776959844805,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck &amp; Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Generalitat de Catalunya Ag\u00e8ncia de Gesti\u00f3 d&apos;Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2022 FI_B 00698"],"award-info":[{"award-number":["2022 FI_B 00698"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.vaccine.2024.04.048","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T19:54:54Z","timestamp":1713470094000},"page":"3474-3485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-042X","authenticated-orcid":false,"given":"Benjamin","family":"Trinit\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-1117","authenticated-orcid":false,"given":"Eberhard","family":"Durr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pons-Gr\u00edfols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5701-7650","authenticated-orcid":false,"given":"Carmen","family":"Aguilar-Gurrieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silveria","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-856X","authenticated-orcid":false,"given":"Victor","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-0126","authenticated-orcid":false,"given":"Ferran","family":"Tarr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Mane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Rovirosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-5948","authenticated-orcid":false,"given":"Jorge","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-0217","authenticated-orcid":false,"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2024.04.048_b0005","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2214-109X(20)30393-4","article-title":"Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study","volume":"9","author":"Wang","year":"2021","journal-title":"Lancet Glob Heal"},{"issue":"12","key":"10.1016\/j.vaccine.2024.04.048_b0010","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/vaccines10122092","article-title":"Rate of hospitalizations and mortality of respiratory syncytial virus infection compared to influenza in older people: a systematic review and meta-analysis","volume":"10","author":"Maggi","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.048_b0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40121-020-00390-7","article-title":"Socioeconomic impact of RSV hospitalization","volume":"10","author":"Young","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"15","key":"10.1016\/j.vaccine.2024.04.048_b0020","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J Virol"},{"issue":"6136","key":"10.1016\/j.vaccine.2024.04.048_b0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.vaccine.2024.04.048_b0030","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.048_b0035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.048_b0040","doi-asserted-by":"crossref","unstructured":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531\u20137. Accessed April 3, 2023. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9724660.","DOI":"10.1542\/peds.102.3.531"},{"issue":"6","key":"10.1016\/j.vaccine.2024.04.048_b0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpedi.1986.02140200053026","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.048_b0050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1086\/517376","article-title":"Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults","volume":"177","author":"Falsey","year":"1998","journal-title":"J Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2024.04.048_b0055","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/S0264-410X(03)00355-4","article-title":"Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies","volume":"21","author":"Piedra","year":"2003","journal-title":"Vaccine"},{"issue":"6158","key":"10.1016\/j.vaccine.2024.04.048_b0060","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"Hsieh","year":"2013","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.vaccine.2024.04.048_b0065","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.celrep.2016.04.078","article-title":"High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells","volume":"15","author":"Ingale","year":"2016","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.048_b0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.immuni.2016.08.016","article-title":"HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies","volume":"45","author":"Steichen","year":"2016","journal-title":"Immunity"},{"issue":"6133","key":"10.1016\/j.vaccine.2024.04.048_b0075","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.04.048_b0080","doi-asserted-by":"crossref","unstructured":"Blanco JCG, Fernando LR, Zhang W, et al. Alternative virus-like particle-associated prefusion F proteins as maternal vaccines for respiratory syncytial virus. Dutch RE, ed. J Virol. 2019;93(23). doi:10.1128\/JVI.00914-19.","DOI":"10.1128\/JVI.00914-19"},{"key":"10.1016\/j.vaccine.2024.04.048_b0085","doi-asserted-by":"crossref","unstructured":"Cox RG, Erickson JJ, Hastings AK, et al. Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model. Lyles DS, ed. J Virol. 2014;88(11):6368\u201379. doi:10.1128\/JVI.00332-14.","DOI":"10.1128\/JVI.00332-14"},{"issue":"9","key":"10.1016\/j.vaccine.2024.04.048_b0090","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/v12090906","article-title":"Two RSV platforms for G, F, or G+F proteins VLPs","volume":"12","author":"Ha","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.04.048_b0095","first-page":"13","article-title":"Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice","author":"Luo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.04.048_b0100","doi-asserted-by":"crossref","unstructured":"McGinnes Cullen L, Luo B, Wen Z, Zhang L, Durr E, Morrison TG. The respiratory syncytial virus (RSV) G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate. Dutch RE, ed. J Virol 2023;97(1). doi:10.1128\/jvi.01900-22.","DOI":"10.1128\/jvi.01900-22"},{"key":"10.1016\/j.vaccine.2024.04.048_b0105","doi-asserted-by":"crossref","unstructured":"McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein. Lyles DS, ed. J Virol 2015;89(13):6835\u201347. doi:10.1128\/JVI.00384-15.","DOI":"10.1128\/JVI.00384-15"},{"issue":"6","key":"10.1016\/j.vaccine.2024.04.048_b0110","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.048_b0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.048_b0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-023-00648-4","article-title":"An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses","volume":"8","author":"Tarr\u00e9s-Freixas","year":"2023","journal-title":"npj Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.048_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24109025","article-title":"Exploring FeLV-gag-based VLPs as a new vaccine platform\u2014analysis of production and immunogenicity","volume":"24","author":"Ortiz","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.vaccine.2024.04.048_b0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV","volume":"23","author":"Joyce","year":"2016","journal-title":"Nat Struct Mol Biol"},{"issue":"18","key":"10.1016\/j.vaccine.2024.04.048_b0135","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1016\/S0021-9258(18)81623-4","article-title":"Fatty acid acylation of the fusion glycoprotein of human respiratory syncytial virus","volume":"264","author":"Arumugham","year":"1989","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.048_b0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1099\/vir.0.81481-0","article-title":"The cytoplasmic domain of the F protein of Human respiratory syncytial virus is not required for cell fusion","volume":"87","author":"Branigan","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2024.04.048_b0145","doi-asserted-by":"crossref","unstructured":"Flynn JA, Durr E, Swoyer R, et al. Stability characterization of a vaccine antigen based on the respiratory syncytial virus fusion glycoprotein. Mantis NJ, ed. PLoS One 2016;11(10):e0164789. doi:10.1371\/journal.pone.0164789.","DOI":"10.1371\/journal.pone.0164789"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.048_b0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nm.2071","article-title":"Generation of stable monoclonal antibody\u2013producing B cell receptor\u2013positive human memory B cells by genetic programming","volume":"16","author":"Kwakkenbos","year":"2010","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2024.04.048_b0155","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/19420862.2019.1654304","article-title":"Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV\/hMPV cross-neutralizing epitopes","volume":"11","author":"Xiao","year":"2019","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.048_b0160","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41467-022-30205-x","article-title":"Profiling of hMPV F-specific antibodies isolated from human memory B cells","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.048_b0165","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/jvi.63.7.2941-2950.1989","article-title":"Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function","volume":"63","author":"Beeler","year":"1989","journal-title":"J Virol"},{"issue":"6452","key":"10.1016\/j.vaccine.2024.04.048_b0170","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.04.048_b0175","article-title":"Exploiting the intracellular compartmentalization characteristics of the S. cerevisiae host cell for enhancing primary purification of lipid-envelope virus-like particles","author":"Kee","year":"2009","journal-title":"Biotech. Prog. Published online"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.048_b0180","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/bp070472i","article-title":"Study of detergent-mediated liberation of hepatitis B virus-like particles from S. cerevisiae homogenate: identifying a framework for the design of future-generation lipoprotein vaccine processes","volume":"24","author":"Kee","year":"2008","journal-title":"Biotechnol Prog"},{"issue":"6","key":"10.1016\/j.vaccine.2024.04.048_b0185","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/jps.21152","article-title":"Endotoxin limits in formulations for preclinical research","volume":"97","author":"Malyala","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2024.04.048_b0190","doi-asserted-by":"crossref","unstructured":"Cimica V, Boigard H, Bhatia B, et al. Novel respiratory syncytial virus-like particle vaccine composed of the postfusion and prefusion conformations of the F glycoprotein. Pasetti MF, ed. Clin Vaccine Immunol 2016;23(6):451\u20139. doi:10.1128\/CVI.00720-15.","DOI":"10.1128\/CVI.00720-15"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.048_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7010021","article-title":"Comparison of immune responses to different versions of VLP associated stabilized RSV pre-fusion F protein","volume":"7","author":"Cullen","year":"2019","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.048_b0200","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.181.2.713","article-title":"T cell genetic background determines default T helper phenotype development in vitro","volume":"181","author":"Hsieh","year":"1995","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.04.048_b0205","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00024382-200210000-00009","article-title":"Genetic contribution to the septic response in a mouse model","volume":"18","author":"Stewart","year":"2002","journal-title":"Shock"},{"issue":"4","key":"10.1016\/j.vaccine.2024.04.048_b0210","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nsmb.2250","article-title":"Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site","volume":"19","author":"Wen","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2024.04.048_b0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/bs.mie.2016.09.013","article-title":"Filter-aided sample preparation: the versatile and efficient method for proteomic analysis","volume":"585","author":"Wi\u015bniewski","year":"2017","journal-title":"Methods Enzymol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T20:56:24Z","timestamp":1716843384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24004730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":43,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0264410X24004730"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}